Overview

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Status:
Completed

Trial end date:
2018-05-29

Target enrollment:

Participant gender:

Summary

The trial was designed to evaluate the incidence of unintended hypophosphatemia (low level of phosphate in the blood) in subjects with iron deficiency anaemia (IDA).

Phase:

Phase 3

Details

Lead Sponsor:

Pharmacosmos A/S

Treatments:

Ferric Compounds
Iron
Iron isomaltoside 1000